Escuche esta historia
--:--
1:26
WHO recommends molnupiravir in patients with Covid-19 who are not at high risk
The treatment should be taken twice a day for five days.
In the list of recommended treatments against Covid-19 of the World Health Organization (WHO), the antiviral molnupiravir is now included.
This would be the first oral drug which is recommended by the body, against Covid-19.
The use of this drug is recommended in patients who do not have a serious disease, but who are at high risk of possible hospitalization.
The people who use this medicine would be those who have not been inoculated until now, patients with immunological deficiencies, or chronic diseases and the elderly.
In children and pregnant or lactating women, the WHO prohibits the drug.
This drug is produced by the German firm Merck and is consumed through pills. The organization advises that it be taken with the first symptoms of infection, since this way hospitalization would be avoided.
It is recommended to consume twice a day, four pills of the drug (a total of 800 milligrams), for five days, time in which the symptoms of the disease develop.
These recommendations are based on information obtained from six randomized trials in which 4,796 patients participated.
In 2021, Doctors Without Borders reported that this 5-day treatment could cost $700. However, if developed with alternative generics, the full treatment would cost $20. In India, the generic manufacture of said pill is already being carried out.
